124 related articles for article (PubMed ID: 2220756)
1. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders.
Katoh O; Kimura A; Itoh T; Kuramoto A
Am J Hematol; 1990 Nov; 35(3):145-50. PubMed ID: 2220756
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders.
Katoh O; Kimura A; Kuramoto A
Am J Hematol; 1988 Apr; 27(4):276-80. PubMed ID: 3354562
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
[TBL] [Abstract][Full Text] [Related]
4. Analysis of c-sis/PDGF-B mRNA expression in megakaryocytic cells of patients with myeloproliferative disorders.
Kanz L; Luig A; Mielke R; Azemar M; Fauser AA; Schaefer HE
Prog Clin Biol Res; 1990; 356():287-98. PubMed ID: 2217445
[No Abstract] [Full Text] [Related]
5. [Basic and clinical study of platelet-derived growth factor gene expression].
Takimoto Y; Kimura A
Rinsho Ketsueki; 1994 Apr; 35(4):364-9. PubMed ID: 8028181
[TBL] [Abstract][Full Text] [Related]
6. Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
Kimura A; Katoh O; Kuramoto A
Br J Haematol; 1988 Jun; 69(2):153-6. PubMed ID: 3390390
[TBL] [Abstract][Full Text] [Related]
7. Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets.
Hashizume S; Akaike M; Azuma H; Ishikawa K; Yoshida S; Sumitomo-Ueda Y; Yagi S; Ikeda Y; Iwase T; Aihara K; Abe M; Sata M; Matsumoto T
J Atheroscler Thromb; 2011; 18(2):138-47. PubMed ID: 21060209
[TBL] [Abstract][Full Text] [Related]
8. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
9. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
10. Megakaryocytes and platelets in myeloproliferative disorders.
Briere J; Kiladjian JJ; Peynaud-Debayle E
Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
[TBL] [Abstract][Full Text] [Related]
11. Platelet PDGF and TGF-β Levels in Myeloproliferative Disorders.
Martyré MC
Leuk Lymphoma; 1991; 6(1):1-6. PubMed ID: 27457569
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
13. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
14. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Gersuk GM; Carmel R; Pattengale PK
Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368
[TBL] [Abstract][Full Text] [Related]
15. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
16. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
17. Human megakaryocytes. III. Characterization in myeloproliferative disorders.
Rabellino EM; Levene RB; Nachman RL; Leung LL
Blood; 1984 Mar; 63(3):615-22. PubMed ID: 6230121
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
19. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
20. [Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes].
Brière J; Kiladjian JJ; Peynaud-Debayle E
C R Seances Soc Biol Fil; 1996; 190(5-6):533-9. PubMed ID: 9074718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]